According to the release, the RESULT clinical trial is a Phase 3 study of Sollpura for the treatment of Exocrine Pancreatic Insufficiency, also known as EPI. ANTH announced that the second, and final, interim futility analysis was conducted by RESULT’s Data Monitoring Committee. This committee is comprised of experts appointed by the Cystic Fibrosis Foundation’s Therapeutics Development Network. The company said that it is on track to report topline data later this quarter. In a statement, Craig Thompson, President and CEO at ANTH, had the following to offer:
The positive interim futility analysis of the RESULT study represents one of the last clinical milestones ahead of topline data this quarter… We look forward to sharing the study outcome shortly and potentially providing patients with a new treatment option for their exocrine pancreatic insufficiency therapy.
What We’re Seeing From The Stock
One of the first things that we learn is that the news moves the market. In this particular case, the news surrounding ANTH and their clinical results proved to be overwhelmingly positive. So naturally, we’re seeing a strong reaction to the news in the market. At the moment (12:39), ANTH is trading at $1.37 per share after a gain of $0.09 per share or 7.03% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!